Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results von Sallman, David Andrew, Al Malki, Monzr, Asch, Adam Steven, Lee, Daniel Junseung, Kambhampati, Suman, Donnellan, William Bruce, Bradley, Terrence James, Vyas, Paresh, Jeyakumar, Deepa, Marcucci, Guido, Komrokji, Rami S., Van Elk, Joanna, Lin, Ming, Maute, Roy, Volkmer, Jens-Peter, Takimoto, Chris H.M., Chao, Mark, Daver, Naval Guastad

Volltext

The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results von Sallman, David Andrew, Donnellan, William Bruce, Asch, Adam Steven, Lee, Daniel Junseung, Al Malki, Monzr, Marcucci, Guido, Pollyea, Daniel Aaron, Kambhampati, Suman, Komrokji, Rami S., Van Elk, Joanna, Lin, Ming, Agoram, Balaji, Chen, James Y, Volkmer, Jens-Peter, Takimoto, Chris H.M., Chao, Mark, Vyas, Paresh

Volltext